Search

Author/Creator Rini, B I

2. 873PSafety and tolerability of atezolizumab (atezo) plus bevacizumab (bev) vs sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC): Pooled analysis of IMmotion150 and IMmotion151. (23rd October 2018)

Authors:
Suarez, C; Choueiri, T K; McDermott, D F; Escudier, B; Atkins, M B; Powles, T B; Rini, B I; Motzer, R J; Pal, S K; Fong, L; De Giorgi, U; Wang, Y; Khaznadar, T; Di Nucci, F; Kaiser, C; Tayama, D; Donskov, F
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 874PTreatment-free interval (TFI) following discontinuation of first-line nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with advanced renal cell carcinoma (aRCC): CheckMate 214 analysis. (23rd October 2018)

Authors:
McDermott, D F; Rini, B I; Motzer, R J; Tannir, N M; Escudier, B; Kollmannsberger, C K; Hammers, H J; Porta, C; George, S; Donskov, F; Gurney, H P; Grimm, M-O; Harrison, M; Hutson, T E; Doan, J; Yang, S; Rao, S; Mekan, S; Ambavane, A; Powles, T
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 875PCharacterization of response to nivolumab plus ipilimumab (N+I) or sunitinib (S) in patients (Pts) with previously untreated advanced renal cell carcinoma (arcc): Checkmate 214. (23rd October 2018)

Authors:
Rini, B I; Tannir, N M; Escudier, B; McDermott, D F; Grimm, M-O; Porta, C; Powles, T; Kollmannsberger, C K; Gurney, H P; Tykodi, S S; Harrison, M; Heng, D Y C; Grünwald, V; Choueiri, T K; Mekan, S; McHenry, M B; Hammers, H J; Motzer, R J; George, S
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. LBA31Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). (23rd October 2018)

Authors:
Rini, B I; Huseni, M; Atkins, M B; McDermott, D F; Powles, T B; Escudier, B; Banchereau, R; Liu, L-F; Leng, N; Fan, J; Doss, J; Nalle, S; Carroll, S; Li, S; Schiff, C; Green, M; Motzer, R J
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search